Ƶ

New Auvelity Data; Yale's Mental Health Lawsuit; Depression Nasal Spray Fast-Tracked

— News and commentary from the psychiatry world

Ƶ MedicalToday
Illustration of a brain shaped maze.

The antidepressant achieved rapid and sustained improvements in both cognitive and physical functioning in people with major depressive disorder in the 12-month EVOLVE trial, Axsome Therapeutics announced.

Having at least one cut the amount of overall medical spending for patients with a newly diagnosed behavioral health condition. (JAMA Network Open)

Could the be causing vast heterogeneity of cases? (JAMA Psychiatry)

Students filed a for alleged "systemic discrimination" against students with mental health disabilities. (NBC News)

People in a Danish study diagnosed with a mental illness versus the general population -- mostly stemming from longer stretches of unemployment and time receiving a disability pension. (The Lancet Psychiatry)

The FDA granted fast track designation for the for major depressive disorder, Vistagen announced.

Very few after not fully responding to cognitive behavioral therapy, despite pharmacotherapy being associated with significant improvement in symptoms. (Journal of Clinical Psychiatry)

An analysis of uncovered a rise in the use of drugs including fentanyl and amphetamines early on in the pandemic. The biggest increase was marked by a 286% rise in MDMA use. (Society for Risk Analysis Annual Meeting)

Biogen and Sage Therapeutics announced that for major depressive disorder has officially been sent over to the FDA.

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.